TNS3: A novel drug target and biomarker for the treatment of neurodegenerative diseases

Target Name: TNS3

NCBI ID: G64759

TNS3

TNS3: A novel drug target and biomarker for the treatment of neurodegenerative diseases

Abstract:
TNS3, a member of the Tensin-like SH2 domain family, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. This protein plays a crucial role in the regulation of cellular processes, including cell adhesion, migration, and survival. TNS3 dysfunction has been implicated in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The discovery of TNS3 as a drug target and biomarker holds great promise for the development of new therapeutic approaches for these debilitating conditions.

Introduction:
Neurodegenerative diseases are a group of disorders that affect the nervous system and can lead to progressive loss of cognitive, motor, and other functions. These conditions are often irreversible and can significantly impact the quality of life of affected individuals. The development and progression of neurodegenerative diseases are influenced by a complex interplay of genetic and environmental factors, making them difficult to treat. Therefore, the identification of new drug targets and biomarkers is crucial for the development of effective therapies.

TNS3: A novel drug target and biomarker

The Tensin-like SH2 domain is a protein that belongs to the protein family TTC1 (Tensin-like domain containing 1). This family is characterized by the presence of a conserved catalytic core and a variable region that includes multiple domains, including the SH2 domain. The SH2 domain is a well-established protein-ligand interface that is involved in various cellular processes, including protein-protein interactions, DNA binding, and regulation of cellular processes.

TNS3, a member of the TCS1 family, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. The TNS3 protein has been shown to play a crucial role in the regulation of cellular processes, including cell adhesion, migration, and survival. TNS3 has also been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

Drug targeting TNS3

TNS3 can be a potential drug target for the treatment of neurodegenerative diseases due to its involvement in the regulation of cellular processes that are affected in these conditions. For example, TNS3 has been shown to play a role in the regulation of neurotrophin (NT) signaling, which is a critical factor in the development and progression of neurodegenerative diseases.

TNS3 has also been shown to play a role in the regulation of PDGF signaling, which is a critical factor in the development and progression of certain neurodegenerative diseases. PDGF signaling is a complex signaling pathway that involves the interaction between PDGF proteins and various downstream targets, including TNS3.

Biomarker potential

TNS3 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. The regulation of TNS3 activity has been shown to be involved in the development and progression of various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Therefore, TNS3 may be a useful biomarker for the diagnosis and monitoring of these conditions.

Discovery of TNS3 as a drug target

The discovery of TNS3 as a potential drug target and biomarker for the treatment of neurodegenerative diseases has the potential to revolutionize the treatment of these conditions. Currently, there are no approved drugs that specifically target TNS3. Therefore, the development of new therapeutic approaches that target TNS3

Protein Name: Tensin 3

Functions: May act as a protein phosphatase and/or a lipid phosphatase (Probable). Involved in the dissociation of the integrin-tensin-actin complex (PubMed:17643115). EGF activates TNS4 and down-regulates TNS3 which results in capping the tail of ITGB1 (PubMed:17643115). Increases DOCK5 guanine nucleotide exchange activity towards Rac and plays a role in osteoclast podosome organization (By similarity). Enhances RHOA activation in the presence of DLC1 (PubMed:26427649). Required for growth factor-induced epithelial cell migration; growth factor stimulation induces TNS3 phosphorylation which changes its binding preference from DLC1 to the p85 regulatory subunit of the PI3K kinase complex, displacing PI3K inhibitor PTEN and resulting in translocation of the TNS3-p85 complex to the leading edge of migrating cells to promote RAC1 activation (PubMed:26166433). Meanwhile, PTEN switches binding preference from p85 to DLC1 and the PTEN-DLC1 complex translocates to the posterior of migrating cells to activate RHOA (PubMed:26166433). Acts as an adapter protein by bridging the association of scaffolding protein PEAK1 with integrins ITGB1, ITGB3 and ITGB5 which contributes to the promotion of cell migration (PubMed:35687021). Controls tonsil-derived mesenchymal stem cell proliferation and differentiation by regulating the activity of integrin ITGB1 (PubMed:31905841)

The "TNS3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TNS3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets